NEWS DESK

DRI Stock News, News Score & What It Could Mean

DRI is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently positive earnings tone.

HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$196.06
Trend Context
Mixed / range
Latest briefing

What's happening with DRI

globenewswire.com9 Jul 2026

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell…

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com1 Jul 2026

Dividend Announcements: June 20-26, 2026

In this article series, I summarize dividend announcements of the past week. Thirteen companies in my database (including 7 banks) announced dividend increases. JPMorgan Chase stands out with a 10% dividend hike, an A+ safety grade, and a new $50B buyback, and trades only 3.35% above fair value. Matson is the week's high-quality non-bank, boasting a 7.34 quality score, 9.4 safety score, and a conservative 10% payout ratio.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
proactiveinvestors.com25 Jun 2026

Darden Restaurants posts mixed fourth quarter results as revenue falls short of estimates

Darden Restaurants Inc (NYSE:DRI) reported mixed fiscal fourth quarter results on Thursday, with adjusted earnings slightly exceeding Wall Street expectations while revenue came in just below analyst estimates. For the quarter ended May 31, 2026, Darden reported adjusted earnings per share from continuing operations of $3.66, topping the consensus estimate of $3.63.

Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
247wallst.com
23 Jun 2026
Here Are Tuesday's Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike, SpaceX, Synopsys, Target, and More
Read ↗
investopedia.com
22 Jun 2026
5 Things to Know Before the Stock Market Opens
Read ↗
barrons.com
21 Jun 2026
Inflation Data, FedEx, Micron, KB Home, Darden, and More to Watch This Week
Read ↗
fool.com
10 Jun 2026
Bloomin' Brands vs. Texas Roadhouse: Which Casual Restaurant Chain Is a Better Buy in 2026?
Read ↗
forbes.com
3 Jun 2026
Here's Where We're Finding Cheap Dividends While Everyone Chases AI
Read ↗
globenewswire.com
1 Jun 2026
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Read ↗
Earnings news

DRI earnings headlines

This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.

1
globenewswire.com9 Jul 2026

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data f

2
zacks.com2 Jul 2026

Darden Stock Outlook Centers on Growth Brands and Cost Risks

DRI enters fiscal 2027 with growth from LongHorn, digital initiatives and new restaurants, while inflation and cautious spending test margins.

Beyond the headline

A deeper look for beginners

Generate a short AI read that goes beyond the headlines above, plus a plain-English breakdown of what it could mean going forward.

Continue your DRI research
Use the stock analysis page for a fuller technical read, open TradingView for charting, or head to Platforms when you are ready to place a trade.